Eli Lilly's logo is shown in one of the company's offices in San Diego, California, on September 17, 2020.
Mike Blake | Reuters
Eli Lilly It is demanding two pharmacies for aggravating Zepbound and Mounjaro, claiming that companies are bordering the prohibition of the practice of food and medication administration and away people from Lilly medicines.
In demands filed on Tuesday in Delaware and New Jersey, Lilly alleges that the two companies, strive for the Pharmacy and the Empower pharmacy, are falsely marketing their products as personalized versions of the medications that have been tested clinically and are carried out using strict safety standards. Lilly argues that these statements are turning people towards compound drugs and far from their treatments approved by the FDA.
Strive and Empower did not immediately respond to CNBC's requests.
It was supposed that pharmacies and compound outsourcing facilities stopped making their own Tirzepatide versions, the active ingredient in the medication for lilly weight loss at zero and the treatment of Mounjaro diabetes, last month after the FDA determined that the brand versions were no longer scarcity. Some continued to aggravate, adjusting the doses and combining them with vitamins, distinctions that make them different from Lilly's drugs and potentially allow them to avoid the prohibition of the FDA.
An Zepbound's injection pen, Eli Lilly's weight loss medication, is shown in New York City on December 11, 2023.
Brendan McDermid | Reuters
Lilly argues that Strive and Empower are simply producing altered Tirzepatide versions instead of customizing them. Brand medications are allowed to compose on a large scale when they are scarcity. Outside that, personalized versions can be made for unique situations, as if a person is allergic to an ingredient or cannot take the form of the drug in which it is normally sold.
Efort and empower the supply Tirzepatide to popular telesalud sites, including Lavender Sky Health and Mochi Health. Companies did not immediately respond to CNBC's requests.
These demands will be Lilly's first test to assume composed pharmacies in the court now that Zepbound and Mounjaro are out of the FDA scarcity list. And they could provide a roadmap for Novo Nordisk, whose obesity of the medicine and diabetes treatment, Ozempic generally cannot be aggravated after the end of May.
